Press releases

Appointment of Pascal SIRVENT to the Board of Directors

August 30th 2018

VALBIOTIS strengthens its Board of Directors and announces the appointment of Pascal SIRVENT.

Read more

Half-year report of the liquidity contract – July 2018 (in French)

July 17th 2018

VALBIOTIS presents the half-year report of its liquidity contract (in French)

Read more

VALBIOTIS confirms its deployment in the United-States, to prepare the future commercialization of VALEDIA

June 7th 2018

VALBIOTIS announces its integration into the French Tech in Boston, Massachusetts, and the development of its investors relations in the USA.

Read more

Annual results 2017

April 3rd 2018

VALBIOTIS announces its consolidated results for 2017 and presents a progress report on its development program.

Read more

2018 financial communication calendar

February 23rd 2018

VALBIOTIS presents its next financial communication milestones for 2018.

Read more

HALF-YEAR REPORT OF THE LIQUIDITY CONTRACT WITH PORTZAMPARC, WITH INCREASED LIQUIDITY

January 31st 2018

VALBIOTIS presents the half-year report of the Liquidity contract with PORTZAMPARC and announces that its means are increased (in French)

Read more

consolidated results for the first half of 2017

September 29th 2017

VALBIOTIS announced its consolidated results for the first half of 2017 and major progress in clinical studies.

Read more

International pharmaceutical and nutrition expert Dr. Jean Zetlaoui joins VALBIOTIS’ Supervisory Board

September 20th 2017

VALBIOTIS announced the arrival of Jean ZETLAOUI on Valbiotis’ Supervisory Board.

Read more

VALBIOTIS: Pascal SIRVENT appointed Director of Discovery and Preclinical Research

September 14th 2017

VALBIOTIS announced the arrival of Pascal SIRVENT as Director of Discovery and Preclinical Research from September 1st, 2017.

Read more

VALBIOTIS opens a new Clinical Investigation Center at the Institut Pasteur in Lille as part of the Phase IIa study on TOTUM-63, the active ingredient of Valedia®

September 6th 2017

The opening of this new Clinical Investigation Center at the Institut Pasteur in Lille which follows the opening of the first Biofortis Mérieux NutriSciences Clinical Investigation Center in Nantes in November 2016 will help accelerate the recruitment of volunteers for the Phase IIa clinical study.

Read more

RESULTS OF PHASE I/II CLINICAL STUDY ON THE ACTIVE INGREDIENT OF VALEDIA®

June 9th 2017

VALBIOTIS will present the results of its Phase I/II clinical study on the active ingredient of Valedia®, TOTUM-63, during the 77th Scientific Sessions of the American Diabetes Association.

Read more

VALBIOTIS INITIAL PUBLIC OFFERING RECORDS HUGE SUCCESS

June 2nd 2017

VALBIOTIS has announced today the huge success of its initial public offering and the admission of its shares for trading on Alternext Paris (ISIN code: FR0013254851 and mnemonic code: ALVAL).

Read more

SEBASTIEN PELTIER, CEO OF VALBIOTIS, PRESENTS HIS VISION OF A DIABETES-FREE WORLD AT L’ÉCHAPPÉE VOLÉE

April 24th 2017

Sébastien PELTIER has been selected to share his vision of a diabetes-free world at l’Echappée Volée from 12 to 14 May in Chantilly, France.

Read more

TWO PARTNERSHIP AGREEMENTS TO ASSESS THE EFFECTS OF TOTUM-63, THE ACTIVE INGREDIENT OF VALEDIA®, ON INTESTINAL MICROBIOTA

April 12th 2017

VALBIOTIS has announced the signing of two partnership agreements, one with Biofortis (Merieux NutriSciences), and the other with the Université Catholique de Louvain (Belgium) and Prof. Patrice D. Cani1 (PhD) as part of a program aimed at evaluating the efficacy of TOTUM-63, the active ingredient of Valedia®, on intestinal microbiota.

Read more